OIL December 2024 Quarterly Report and Appendix 4C

• Signed Collaborative Research Agreement with University of Minnesota for veterinary imaging
• Commenced development of dedicated veterinary imaging device
• Delivered first flexible GI scope prototype to University Medical Centre of the Johannes Gutenberg University Mainz
• Substantial progress on InVue product development

Optiscan Imaging Ltd (ASX:OIL) reported a highly successful December 2024 quarter, advancing its core priorities across R&D, commercialization, and market expansion. Key highlights included the signing of a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine to explore clinical applications of confocal imaging in companion animals, and the commencement of development on a dedicated veterinary imaging device. The company also delivered its first flexible GI scope prototype to the University Medical Centre of the Johannes Gutenberg University Mainz for evaluation, and made substantial progress on the InVue product development program. Optiscan's sales pipeline continued to grow, particularly in the U.S. pre-clinical imaging market with the ViewnVivo system. The company also engaged in various marketing and communications initiatives to enhance its public profile and showcase its innovative technology. Optiscan remains firmly on track to deliver on its strategic priorities, with a continued focus on advancing multiple parallel R&D projects and securing additional funding and partnerships to support its growth.

Optiscan received $0.398m in grant funding during the quarter as part of its $3m Cooperative Research Centres Projects (CRC-P) project for the development of an Edge-AI-enabled gastrointestinal flexible endomicroscope. The company also secured an Advance Overseas Finding through AusIndustry, allowing it to claim R&D tax incentives on eligible overseas costs, providing rebates exceeding $0.5m annually with respect to FY24 and beyond.

Optiscan remains firmly on track to deliver on its strategic priorities for R&D and clinical advancements, with a continued focus on advancing multiple parallel projects including Surgical (InVue), Pathology, Gastrointestinal, Telepathology, and Robotics. The company is well-positioned to propel into its next phase of growth, delivering innovative imaging solutions that create value for both the medical community and shareholders.